Review



mouse hprt1 transcripts  (Integrated DNA Technologies)


Bioz Verified Symbol Integrated DNA Technologies is a verified supplier
Bioz Manufacturer Symbol Integrated DNA Technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Integrated DNA Technologies mouse hprt1 transcripts
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Mouse Hprt1 Transcripts, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 95/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+hprt1+transcripts/pmc09177980-160-0-37?v=Integrated+DNA+Technologies
    Average 95 stars, based on 4 article reviews
    mouse hprt1 transcripts - by Bioz Stars, 2026-08
    95/100 stars

    Images

    1) Product Images from "Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS"

    Article Title: Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS

    Journal: Nucleic Acids Research

    doi: 10.1093/nar/gkac037

    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Figure Legend Snippet: Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Techniques Used: Expressing, Whisker Assay, Concentration Assay



    Similar Products

    mouse hprt1 transcripts  (Integrated DNA Technologies)
    95
    Integrated DNA Technologies mouse hprt1 transcripts
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Mouse Hprt1 Transcripts, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+hprt1+transcripts/pmc09177980-160-0-37?v=Integrated+DNA+Technologies
    Average 95 stars, based on 1 article reviews
    mouse hprt1 transcripts - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Journal: Nucleic Acids Research

    Article Title: Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS

    doi: 10.1093/nar/gkac037

    Figure Lengend Snippet: Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Article Snippet: Mouse Hprt1 transcripts were quantified with the following primers: forward primer: CAA ACT TTG CTT TCC CTG GTT; reverse primer: TGG CCT GTA TCC AAC ACT TC; probe sequence:/5HEX/AC CAG CAA G/Zen/C TTG CAA CCT TAA CC/3IABkFQ/ (Integrated DNA Technologies).

    Techniques: Expressing, Whisker Assay, Concentration Assay